Cobimetinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and HAS (France), among others, recommended or restricted cobimetinib, while NICE (England) did not recommend it.
Every record falls within a 0.9-year window, 16 Nov 2015 to 26 Oct 2016 — a compressed review cycle.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for cobimetinib, 1 submission was never made — an outcome set by the company rather than the assessor.
Nothing has been added since 2016; on this evidence the file is dormant.
3 distinct indication wordings are recorded for cobimetinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
The systems moved almost together: all 7 agencies opened a file on cobimetinib within a year of one another, starting with AWMSG (Wales) on 16 Nov 2015.
Activity is concentrated rather than steady: 6 of 7 dated records fall in 2016 alone.
7 of the 18 agencies in this archive hold a record for cobimetinib.
The full ledger for cobimetinib reads 4 recommended, 1 not recommended, 1 non-submission and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 26 Oct 2016 | NICE TA414 | not recommended | source |
| AOTMIT (Poland) | 26 Oct 2016 | Cotellic reimbursement recommendation | recommended | source |
| SMC (Scotland) | 12 Sep 2016 | In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. | not recommended | source |
| PBAC (Australia) | 2016 | Unresectable Stage III or IV malignant melanoma | The PBAC recommended the Authority Required (STREAMLINED) listing of vemurafenib in combin… | source |
| G-BA (Germany) | 2 Jun 2016 | Cotellic — benefit assessment §35a | added benefit: considerable (indication) | source |
2 further decisions for cobimetinib, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 7 decisions for cobimetinib from 7 agencies, 2015 to 2016. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.